Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Dose-escalation, and Dose-expansion Phase I Trial of TAA06 Injection in Patients With Relapsed/Refractory Neuroblastoma

Next Previous
Trial Profile

An Open-label, Dose-escalation, and Dose-expansion Phase I Trial of TAA06 Injection in Patients With Relapsed/Refractory Neuroblastoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Apr 2023 According to a PersonGen Biotherapeutics media release, first subject successfully completed CAR-T cell reinfusion in Tianjin Cancer Hospital. The administration of the first patient was successfully completed under the leadership and guidance of Professor Zhao Qiang and with the support of clinical experts in the department.
  • 23 Feb 2023 Status changed from not yet recruiting to recruiting.
  • 01 Nov 2022 Planned initiation date changed from 18 Oct 2022 to 15 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top